Tsuprykov O showed that dipeptidyl peptidase-4 (DPP-4) inhibitor, Linagliptin, has the comparable efficacy to ARB in preventing CKD progression in the 5/6 nephrectomy rats models. This evidence concerns the gene DPP4 and chronic kidney disease.